MedTrace Logo

Hypertension and Cardiovascular Risk Associated With Obstructive Sleep Apnea in Adult in Guadeloupe (French West Indies)

NCT03373357 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2017-12-14

No results posted yet for this study

Summary

The MAPA is the reference method to estimate the PA during the SAHOS. The MAPA can be recommended over 48 hours: indeed, the PA falls at the beginning of every apnea then increases gradually up to a pressif peak arising at the time of the ventilatoire resumption. These variations arise under the influence of 4 stimulus: the désaturation in O2, the rise of the PaCO2, the increase of the respiratory effort and the microawakening of the end of apnea who are at the origin of a sympathetic stimulation.

Consequently a better diagnostic approach of the HTA (confirmation of a resistant HTA, an identification of the masked HTA and the patients " not dipper " by the MAPA), the identification of the SAHOS, and a better coverage) of the associated cardiovascular risk factors are essential and establish a stake in public health.

To investigator's knowledge, no datum or study on the association HTA-SAHOS and its consequences was until then realized in the French overseas departments.

Conditions

  • Hypertension Arterial

Interventions

OTHER

Patient not SAHOS

Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit. * Cardiovascular events arisen during the duration of the study * Modifications of the lifestyle: alcohol, physical activity * Weight * Clinical measure of the PA * Clinical examination * The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients

OTHER

Patient SAHOS sailed by the ventilation in PPC and not sailed

Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore. * Questionnaire of evaluation of the global quality of life of the SAHOS * Appearance of new cardiovascular risk factors * Cardiovascular events arisen during the duration of the study * Modification of the current treatments * Modifications of the lifestyle: alcohol, physical activity * Weight * Clinical measure of the PA * Clinical examination * The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de la Guadeloupe

    lead OTHER

Principal Investigators

  • Rachel BILLY BRISSAC, Dorctor cardiovascular · Hospital University Center of Pointe-à-Pitre

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-09
Primary Completion
2014-11-19
Completion
2019-11-30

Countries

  • Guadeloupe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03373357 on ClinicalTrials.gov